An FDA advisory committee reported that they supported the use of AstraZeneca’s vandetanib for the treatment of patients with medullary thyroid cancer (MTC).
However, they also indicated the drug should be reserved for patients who are experiencing symptoms of their disease due to the substantial toxicity (cerebrovascular events and prolonged QT interval) associated with this drug.
The panel’s recommendations were based in part on the results of a clinical trial that showed a 54-percent reduction in the rate of disease progression in advanced MTC patients treated with vandetanib when compared to placebo.
Please visit healthreason.com for more health related articles.
